Veloxis Pharmaceuticals can breathe easy as LCP-Tacro (tacrolimus), the sole product on which the company's hopes were based, has reported positive Phase III results in de novo kidney transplant patients, keeping the company on track for its planned US regulatory filing.
The News in a Nutshell
Welcome to Scrip
Create an account to read this article
Already a subscriber?